ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
|
|
- Beverly Watson
- 6 years ago
- Views:
Transcription
1 ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK
2 OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity of Acute Myeloid Leukaemia (AML) Importance of heterogeneity to risk stratification and treatment approach Established treatments for AML and the evidence base for these Recent additions to established treatments 4 new drugs regulatory approved in the past 12 months Emerging therapies for AML coming to the clinic soon?
3 DISEASE HETEROGENEITY IMPORTANCE OF CYTOGENETICS Republished with permission of American Society of Hematology from Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Grimwade D, et al., Blood 2010;116(3): ; permission conveyed through Copyright Clearance Center, Inc.
4 DISEASE HETEROGENEITY IMPORTANCE OF CYTOGENETICS Risk Group Proportion of patients Refined MRC Favourable 23% t(15;17) APL t(8;21) Inv(16) or t(16;16) Intermediate 67% Normal karyotype or other noncomplex Adverse 10% Inv(3) or t(3;3) Add(5q), del(5q) or -5 Add(7q), del(7q) or -7 t(11q23) excluding t(9;11) and t(11;19) t(9;22) -17 or abn(17p) Complex ( 4 unrelated abn) Grimwade D, et al., Blood 2010;116(3):
5 DISEASE HETEROGENEITY IMPORTANCE OF MOLECULAR DATA From N Engl J Med, The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. 368: , Copyright 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
6 DISEASE HETEROGENEITY IMPORTANCE OF MOLECULAR DATA From N Engl J Med 2015; Döhner H, et al., Acute Myeloid Leukemia, ;373: Copyright 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
7 DISEASE HETEROGENEITY IMPORTANCE OF MOLECULAR DATA From N Engl J Med, Papaemmanuil E, et al., Genomic Classification and Prognosis in Acute Myeloid Leukemia, 2016;374: Copyright 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
8 DISEASE HETEROGENEITY COMBINING DATA From N Engl J Med, Papaemmanuil E, et al., Genomic Classification and Prognosis in Acute Myeloid Leukemia, 374: Copyright 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
9 DISEASE HETEROGENEITY IMPORTANCE OF COMBINED DATA Combined prognostic score ELN 2017 Risk category Favourable Intermediate Adverse Genetic abnormality t(8:21)(q22;q22); RUNX1-RUNX1T1 inv(16)(p13.1q22)or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated NPM1 without FLT3-ITD or with FLT3-ITD low Biallelic mutated CEBPA Mutated NPM1 and FLT3-ITD high Wild-type NPM1 and without FLT3-ITD or with FLT3-ITD low (without adverse risk cytogenetics) t(9:11) (p22;q23); MLLT3-KMT2A Cytogenetic abnormalities not classified as favourable or adverse t(6;9) (p23;q34); DEK-NUP214 t(v:11) (v;q23); KMT2A rearranged t(9:22)(q43.1:q11.2); BCR-ABL1 Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); GATA2-MECOM (EVI1) -5 or del(5q); -7; -17/abn(17p) Complex karytoype, monosomal karyotype Wild-type NPM1 and FLT3-ITD high Mutated RUNX1 Mutated ASXL1 Mutated TP53 Döhner H, et al., Blood 2017;129(4):
10 WHY IS THIS RELEVANT TO DISCUSSIONS ABOUT THERAPEUTICS? Risk stratification consolidation chemotherapy Subgroup analysis in clinical trials Rational use of targeted therapies groups that should be targeted on biology groups in which treatments are particularly effective/ineffective
11 WHAT ARE THE CURRENT RECOMMENDATIONS FOR INDUCTION THERAPY AND THE EVIDENCE BASE FOR THIS?
12 RANDOMISED TRIALS OF DAUNORUBICIN DOSE IN AML INDUCTION THERAPY Study Group Age Range (y) No. of patients Doses compared Conclusions ECOG mg/m 2 d1-3 vs. 45 mg/m 2 d1-3 HOVON-SAKK- AMLSG > mg/m 2 d1-3 vs 45 mg/m 2 d1-3 Korean Group mg/m 2 d1-3 vs 45 mg/m 2 d1-3 AML17 (NCRI) mg/m 2 d1/3/5 vs 60 mg/m 2 d1/3/5 Higher RR Longer OS Similar toxicity Higher RR Similar OS Similar toxicity Higher RR Improved EFS/ OS Similar toxicity Similar RR Similar EFS/OS Higher early death rate (60d mortality). Fernandez HF, et al., N Engl J Med 2009;361(13): ; Luskin MR, et al., Blood 2014;123(21):373; Löwenburg B, et al., N Engl J Med 2009;361(13): ; Lee JH, et al., Blood 2011;118(14): ; Burnett AK, et al., Blood 2015;125(25):
13 RANDOMISED TRIALS OF DAUNORUBICIN DOSE IN AML INDUCTION THERAPY Lee JH, et al., J Clin Oncol 2017;35(24): Reprinted with permission American Society of Clinical Oncology. All rights reserved.
14 RANDOMISED TRIALS OF DAUNORUBICIN DOSE IN AML INDUCTION THERAPY Lee JH, et al., J Clin Oncol 2017;35(24): Reprinted with permission American Society of Clinical Oncology. All rights reserved.
15 RANDOMISED TRIALS OF CYTARABINE DOSE IN AML INDUCTION THERAPY Study Group Age Range (y) No. of patients Doses compared Conclusions ALSG mg/m 2 12h d1/3/5/7 vs 100mg/m 2 CIV d1-7 SWOG mg/m 2 12h d1-6 vs 200mg/m 2 CIV d1-7 HOVON-SAKK mg/m 2 12h d1-5 vs 200mg/m 2 CIV d1-7 EORTC-GIMEMA mg/m 2 12h d1/3/5/7 vs 200mg/m 2 CIV d1-10 Similar OS Higher early death (not significant) Similar RR Similar OS Higher early death Similar RR Similar EFS Similar OS Higher RR Longer RFS and OS in younger patients ( 45 y) Similar early death Weick JK, et al., Blood 1996;88(8): , Bishop JF, et al., Blood 1996;87(5): Löwenberg B, et al., N Engl J Med 2011;364(11): , Willemze R, et al., J Clin Oncol 2014;32(3)
16 TRIALS OF PURINE ANALOGUES IN COMBINATION WITH INTENSIVE INDUCTION THERAPY IN PREVIOUSLY UNTREATED PATIENTS NCRI trial Age Range (y) No. of patients Treatment arms Conclusions PALG DAC (Cladribine) vs DAF (Fludarabine) vs DA NCRI AML16 > DA vs Dclo (Clofarabine) NCRI AML DA vs ADE (Etoposide) vs FLAG-Ida (Fludarabine) DAC longer OS DAF same OS Similar OS For FLAG-Ida Higher rate of death in CR, Higher CR after course 1. Longer RFS Similar OS Holowiecki J, et al., J Clin Oncol 2012;30(20): Russell NH, et al., Haematologica 2015;100(s1):514 Burnett AK, et al., J Clin Oncol 2013;31(27):
17 FOR PATIENTS ELIGIBLE FOR INTENSIVE INDUCTION THERAPY Suggested approach for induction therapy days of IV anthracycline + 7 days of continuous infusion cytarabine ( mg/m 2 ) Daunorubicin at least 60 mg/m 2 Alternatives include idarubicin 12 mg/m 2 (noting caveats of recent study Lee et al. J Clin Oncol 2017;35: ) Key additional question Does the addition of targeted agents help?
18 RANDOMISED TRIALS OF GEMTUZUMAB OZOGAMICIN (GO) In combination with intensive induction chemotherapy Study Group Age Range (y) No. of patients GO dosing schedule Conclusions SWOG mg/m 2 d4 cycle 1 ALFA mg/m 2 d1/4/7 cycle 1 d1 consol 1 d1 consol 2 GOELAMS mg/m 2 d4 cycle 1 d4 consol 1 EORTC-GIMEMA mg/m 2 D1/15 before cycle 1 Similar RR Similar RFS Similar OS Higher early death Similar RR Improved RFS Improved EFS Improved OS Similar RR Similar EFS Similar OS Similar RR Similar RFS Similar EFS Similar OS Higher early death Petersdorf SH, et al., Blood 2013:121(24): , Castaigne S, et al., Lancet 2012;379(9825): Delaunay J, et al., Blood 2011;118(21):79, Amadori S, et al., J Clin Oncol 2013;31(35):
19 UK-NCRI RANDOMISED TRIALS OF GEMTUZUMAB OZOGAMICIN (GO) In combination with intensive induction chemotherapy NCRI trial Age Range (y) No. of patients GO dosing schedule Conclusions AML mg/m 2 d1 cycle 1 d1 cycle 3 AML16 > mg/m 2 d1 cycle 1 AML vs 6 mg/m 2 d1 cycle 1 Similar RR Similar RFS Similar OS Improved OS in favourable risk Similar RR Improved RFS Improved OS Similar RR Similar OS Lower early death rate with 3 mg/m 2 Burnett AK, et al., J Clin Oncol 2011;29(4): Burnett AK, et al., J Clin Oncol 2012;30(32): Burnett AK, et al., Blood 2014;124(21):2308.
20 META-ANALYSIS OF GEMTUZUMAB OZOGAMICIN Reprinted from The Lancet Oncol 2014; 15 (9). Hills RK, et al., Copyright 2014, with permission from Elsevier. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
21 EFS probability RFS probability CAN WE FURTHER STRATIFY WHO RESPONDS TO GEMTUZUMAB? Months Low/int-CD33+, control High-CD33+, control # at risk: Low/int-CD33+, control Low/int-CD33+, GO High-CD33+, control High-CD33+, GO Low/int-CD33+, GO High-CD33+, GO Months # at risk: Low/int-CD33+, control Low/int-CD33+, GO High-CD33+, control High-CD33+, GO Olombel G, et al., Blood 2017;127(17):
22 CAN WE FURTHER STRATIFY WHO RESPONDS TO GEMTUZUMAB? Lamba JK, et al., J Clin Oncol 2017;35: Reprinted with permission American Society of Clinical Oncology. All rights reserved.
23 CAN WE FURTHER STRATIFY WHO RESPONDS TO GEMTUZUMAB? Lamba JK, et al., J Clin Oncol 2017;35: Reprinted with permission American Society of Clinical Oncology. All rights reserved.
24 OTHER WAYS TO TARGET CD33 Other antibody drug conjugates vadastuximab talirine (SGN-CD33A) Encouraging results from early phase trials Ongoing phase 3 trials CASCADE (NCT ) CAR-T
25 ADDITION OF INHIBITORS OF FLT3 UK MRC AML 15 ( ) All patients R ADE DA 3+10 FLAG-Ida If FLT-3 mutant ADE R DA 3+8 FLAG-Ida R Chemo + CEP-701 Chemo MACE ± Mylotarg Ara-C 1.5g/m 2 ± Mylotarg Ara-C 3g/m 2 ± Mylotarg MidAC Ara-C 1.5g/m 2 Ara-C 3g/m 2 R Ara-C 1.5g/m 2 No further treatment UK NCRI AML 17 ( ) Non-APL patients R ADE ADE+GO3 ADE+GO6 DA+GO3 DA+GO6 Knapper S, et al., Blood 2017; 129(9): R IS K A S S E S S M EN T CBF FLT3 +ve Others Poor risk R R R Chemo Chemo+CEP-701 Chemo+placebo Chemo+mTOR Chemo D Clofarabine FLAG-Ida Consolidation chemotherapy 3v4 courses Ara-C 3g/m 2 for 1 or 2 courses Stem cell transplant
26 Estimated percentage still alive Estimated percentage still alive in CR ADDITION OF INHIBITORS OF FLT3 AML15,17 lestaurtinib randomisation overall survival 100 Annual event rates: Years 1-5 Years 6+ Lestaurtinib 20.6% SD % SD 0.0 No lestaurtinib 23.0% SD % SD years AML15,17 lestaurtinib randomisation relapse free survival 100 Annual event rates: Years 1-5 Years 6+ Lestaurtinib 29.1% SD % SD 2.6 No lestaurtinib 32.9% SD % SD years Allocated lestaurtinib (%±s.d.) Allocated no lestaurtinib (%±s.d.) 1 Deaths/person-years: All patients Lestaurtinib 77/263 55/188 17/140 3/93 1/58 0/59 No lestaurtinib 64/177 37/114 8/89 1/62 2/44 0/ % 44.8% 1.3% SD 5.6 (logrank 2P >0.1; NS) % 46.0% 5 6+ years Allocated lestaurtinib (%±s.d.) Allocated no lestaurtinib (%±s.d.) 1 Events/person-years: All patients Lestaurtinib 124/221 28/131 9/102 3/70 1/43 1/39 No lestaurtinib 90/147 24/80 7/63 0/46 1/35 0/ % SD 6.3 (logrank 2P >0.1; NS) % 38.7% 35.7% 35.7% 5 6+ years Knapper S, et al., Blood 2017; 129(9):
27 Alive (%) Alive (%) Relapsing (%) ADDITION OF INHIBITORS OF FLT3 AML15,17: CIR of CEP-701 patients by inhibition to 85% AML15,17: Survival of CEP-701 patients by inhibition to 85% At risk: Years No inhibition Inhibition At risk: Years No inhibition Inhibition No inhibition Inhibition 2 No. pts No. events No inhibition Inhibition No inhibition Inhibition 3 3 2P= No. pts No. events No inhibition Inhibition P= % 43% 60% 33% AML17: Survival by lestaurtinib concomitant GO and azoles 0 0 Lestaurtinib No lestaurtinib 1 No. pts No. events Lestaurtinib No lestaurtinib At risk: Years Lestaurtinib No lestaurtinib P= % 29% Knapper S, et al., Blood 2017; 129(9):
28 CANCER AND LEUKAEMIA GROUP B (CALGB) (RATIFY) TRIAL 1. Trial design Multi-institutional, multinational, randomised, double-blind, placebo controlled trial Patients years with new diagnosis AML without prior antineoplastic therapy (excluding HU) Patients were screened for FLT3 mutations Enrolled if FLT3 mutant Exclusions included APL, taml, bilirubin 2.5x upper limit normal, major coexisting illness Proposed therapy 1. Standard 3+7 plus midostaurin or placebo (1:1 randomisation) days 8 to For patients achieving CR 4 x HiDAC + midostaurin/placebo days 8 to maintenance cycles of midostaurin/placebo Primary Endpoint overall survival Stone RM, et al., N Engl J Med 2017;377:
29 CANCER AND LEUKAEMIA GROUP B (CALGB) (RATIFY) TRIAL 2. Results Patients and AE 3277 preregistered and screened for FLT3 mutation 896 patients had FLT3 mutation 717 enrolled 68.5% had normal karytoype TKD 22.6% ITD with low allelic ration (0.05 to 0.7) 47.6% ITD with high allelic ration (>0.7) 29.8% Placebo and midostaurin groups well matched apart from female sex (59.4% vs. 51.7% (P=0.04) Anaemia and rash higher in midostaurin group Nausea higher in placebo group No difference in count recovery Stone RM, et al., N Engl J Med 2017;377:
30 CANCER AND LEUKAEMIA GROUP B (CALGB) (RATIFY) TRIAL 2. Results Efficacy outcomes Median follow-up of 59 months for the 359 surviving patients CR rates 58.9% midostaurin vs. 53.5% Placebo (P=0.15) From N Engl J Med, Stone RM, et al., Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation, 2017;377: Copyright 2017 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
31 CANCER AND LEUKAEMIA GROUP B (CALGB) (RATIFY) TRIAL 3. Conclusions and further questions Addition of midostaurin to standard intensive chemotherapy in younger patients with FLT3 mutations improves EFS, DFS, and OS Benefit also seen if received allogeneic transplant in CR1 FDA and EMA approved 2017 for treatment of FLT3 mutant AML Further questions Benefit in particular subgroups of FLT3 mutation? Duration of Rx median duration in trial was 3 months? Is there an independent effect of maintenance Rx? Is it only because of FLT3 targeting? Will the same be seen in 60 years? Stone RM, et al., N Engl J Med 2017;377:
32 Event-free survival (%) TP53 MUTANT AND SECONDARY AML AS SPECIAL CASES? Secondary AML De Novo AML Mutated cases, n (%) P value SRSF2 19 (20) 1 (1) < ZRSR2 7 (8) 0 (0) SF3B1 10 (11) 1 (1) ASXL1 30 (32) 5 (3) < BCOR 7 (8) 2 (2) EZH2 8 (9) 3 (2) U2AF1 15 (16) 8 (4) STAG2 13 (14) 3 (2) 0.07 NF1 6 (6) 7 (4) RUNX1 29 (31) 19 (11) < CBL 5 (5) 3 (2) 0.13 NRAS 21 (23) 15 (8) TET2 19 (20) 17 (9) GATA2 2 (2) 2 (1) 0.6 TP53 14 (15) 16 (9) 0.15 KRAS 7 (8) 8 (4) 0.4 PTPN11 5 (5) 9 (5) 1 IDH1 10 (11) 20 (11) 1 IDH2 10 (11) 19 (11) 1 SMC1A 3 (3) 7 (4) 1 RAD21 2 (2) 5 (3) 1 FLT3 18 (19) 50 (28) 0.14 DNMT3A 18 (19) 51 (28) 0.14 SMC3 2 (2) 7 (4) 0.7 CEBPA 3 (3) 13 (7) 0.28 NPM1 5 (5) 54 (30) < q23-rearranged 0 (0) 11 (6) CBF-rearranged 0 (0) 19 (9) < Odds ratio Clinically-defined de novo AML, Age De novo/pan-aml Secondary-type TP53 mutated Months Lindsley RC, et al., Blood 2015;125(9);
33 TP53 MUTANT AND SECONDARY AML AS SPECIAL CASES? From N Engl J Med, Welch JS, et al., TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes, 2016;(21): Copyright 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
34 Overall survival (%) OLDER PATIENTS SECONDARY AML AS SPECIAL CASES? Overall survival saml patients Deaths / N Median in months 7+3:sAML 18 / (1.4, 7.5) CPX-351:sAML 23 / (9.1, 17.5) Log rank P=value = Months from randomisation Lancet JE, et al., Blood 2014;123(21):
35 OLDER PATIENTS SECONDARY AML AS SPECIAL CASES? Phase 3 study of CPX-351 (NCT ) Reported at ASCO 2016 Patients aged with newly diagnosed high risk (secondary) AML CPX-351 treatment resulted in superior outcomes OS (HR=0.69; P=0.005; median OS 9.56 vs months) EFS (HR=0.74; P=0.021) CR+CRi response (47.7% vs. 33.3%; P=0.016) CPX-351 FDA and EMA approved 2017 for treatment of older patients with t-aml or AML-MRC
36 CONSOLIDATION THERAPY YOUNGER PATIENTS Favourable-risk genetics 2-4 cycles of intermediate dose cytarabine Intermediate-risk cytogenetics Allogeneic transplant 2-4 cycles of intermediate dose cytarabine Adverse-risk cytogenetics Allogenic transplant
37 CONSOLIDATION THERAPY OLDER PATIENTS Favourable-risk genetics 2-4 cycles of intermediate dose cytarabine Intermediate/Adverse-risk cytogenetics No established value of consolidation therapy Consider allogeneic transplant or investigational therapy
38 THE RELAPSED REFRACTORY PATIENT For patients fit enough then reinduction followed by allogeneic transplant Multiple reasons why this may not be possible Patients should be considered for novel agents
39 THE RELAPSED REFRACTORY PATIENT Enasidenib FDA and EMA approved 2017 for relapsed/refractory IDH2 mutant AML Republished with permission of American Society of Hematology from Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Stein E, et al., Blood 2017;130(6):722 31; permission conveyed through Copyright Clearance Center, Inc.
40 MULTIPLE NEW AGENTS IN DEVELOPMENT IDH1 inhibitors New inhibitors of FLT3 BET bromodomain inhibitors DOT1L inhibitors HDAC inhibitors BCL-2 inhibitors Inhibitors of splicing factors
41 SUMMARY Treatment for AML is actually changing 4 new treatments regulatory approved in the last 12 months Precedent set Many encouraging signs of further targeted therapies
42 THANK YOU!
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationFrontline Induc.on Therapy in 2017 Alan K Burne+
Frontline Induc.on Therapy in 2017 Alan K Burne+ Ravenna, October 2017 Standard of Care Induc5on: 7+3 Ara-C / Daunorubicin Consolida5on: High Dose Ara-C (3g doses) Total of 4 courses. Myeloabla5ve allogral
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationAcute Myeloid Leukemia: State of the Art in 2018
Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC Treatment Paradigm of Adults with AML Fit
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationMeet-the-Expert: AML Treating older patients with AML
Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationFLT-3 inhibitors in AML
FLT-3 inhibitors in AML Jorge Sierra Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona Rome, September 24, 2017 Disclosures Advisory board: Pfizer, NovarHs, Jazz, Celgene, SeaIle
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationClinical Overview on Measurable Residual Disease (MRD) in Acute Myeloid Leukemia(AML)
Clinical Overview on Measurable Residual Disease (MRD) in Acute Myeloid Leukemia(AML) Konstanze Döhner Department of Internal Medicine III, University Hospital of Ulm, Ulm Germany DISCLOSURES OF COMMERCIAL
More informationUpdate on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationArecent source data meta-analysis of randomized trials in adults
ARTICLE Acute Myeloid Leukemia EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia:
More informationAcute myeloid leukemia: a comprehensive review and 2016 update
OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia
More informationAcute Myeloid Leukemia
Average annual rate per 100,000 Acute Myeloid Leukemia Guillermo Garcia-Manero Professor Department of Leukemia MD Anderson Cancer Center Putting the Problem into Perspective All other sites (~1,445,000)
More informationSystemic Treatment of Acute Myeloid Leukemia (AML)
Guideline 12-9 REQUIRES UPDATING A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Members of the Acute Leukemia
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationUpdates in the Management of Acute Myeloid Leukemia
Updates in the Management of Acute Myeloid Leukemia Lydia Benitez, harmd, BCO 2017 TOA Conference I have no conflicts of interest with relation to the content of this presentation 4 Objectives Describe
More informationSubset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD. The University of Chicago
Subset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD The University of Chicago Disclosure Information 23 rd Annual Developmental Therapeutics Symposium
More informationLeukaemia - New Therapeutic Approaches. Professor Paresh Vyas
Leukaemia - New Therapeutic Approaches Professor Paresh Vyas Oxford Center for Haematology & MRC Molecular Unit University of Oxford and University of Oxford Hospitals Foundation NHS Trust Outline of Presentation
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationClassification and risk assessment in AML: integrating cytogenetics and molecular profiling
ACUTE MYELOID LEUKEMIA: HOW CAN WE IMPROVE UPON STANDARD THERAPY? Classification and risk assessment in AML: integrating cytogenetics and molecular profiling Matahi Moarii and Elli Papaemmanuil Department
More informationWednesday, November 30, 2011 University of Michigan
Wednesday, November 30, 2011 University of Michigan Presenter Gary J. Schiller, MD, FACP Professor, Department of Medicine, Hematology/Oncology Director, Hematological Malignancies/Stem Cell Transplantation
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationThe Evolving Treatment Landscape in AML
The Evolving Treatment Landscape in AML Elias Jabbour, MD Associate Professor Section Chief, Acute Lymphocytic Leukemia Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More information2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA
2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA Adriano Venditti Ematologia Universita Tor Vergata, Roma Current Treatment Results in AML AGE, y CR%
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationAcute Leukemia. Sebastian Giebel. Geneva 03/04/
Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012 www.ebmt.org Acute leukemias: EBMT survey 2 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant 2009 3 Acute leukemias: INCIDENCE
More informationAcute Myeloid Leukemia
The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. From the Department of
More information«Adverse Prognosis» Acute Myeloid Leukemia
23. Fortbildungskurs Lausanne, 11.11.2017 «Adverse Prognosis» Acute Myeloid Leukemia Markus G. Manz Zentrum für Hämatologie und Onkologie UniversitätsSpital Zürich Content AML Update on current definition
More informationUpdate on Optimal Management of Acute Myeloid Leukemia
Update on Optimal Management of Acute Myeloid Leukemia Fuad El Rassi, Emory University Martha Arellano, Emory University Journal Title: Clinical Medicine Insights: Oncology Volume: Volume 7 Publisher:
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationChanging AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Co-Moderators: Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society Mike
More informationTrapianto allogenico convenzionale
Il trapianto nella leucemia acuta mieloide a rischio intermedio Trapianto allogenico convenzionale Trapianto allogenico nelle Leucemie Acute Mieloidi in I RC D. Pastore Ematologia con Trapianto-Bari Domenico
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationNovel Induction and Targeted Strategies in Acute Myeloid Leukemia
Novel Induction and Targeted Strategies in Acute Myeloid Leukemia Eytan M. Stein, MD Leukemia Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Current Paradigms
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Gemtuzumab ozogamacin for untreated de novo acute myeloid leukaemia Response to consultee and commentator comments re-scope Please note: Comments received in the course
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationCytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Acute Myeloid Leukemia Articles Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Bruno C. Medeiros, 1 Megan Othus, 2,3 Min Fang, 3,4 Frederick R. Appelbaum,
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationAcute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far
Acute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far Martin S. Tallman, M.D. Chief, Leukemia Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationLeucemia Mieloide Acuta Terapie Innovative. Adriano Venditti Ematologia Universita Tor Vergata, Roma
Leucemia Mieloide Acuta Terapie Innovative Adriano Venditti Ematologia Universita Tor Vergata, Roma Leucemia Mieloide Acuta Terapie Innovative Adriano Venditti Ematologia Universita Tor Vergata, Roma AML.Current
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Effective Date: June, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team and are a synthesis of currently accepted
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationSUPPLEMENTAL APPENDIX METZELER ET AL.: SPECTRUM AND PROGNOSTIC RELEVANCE OF DRIVER GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA
SUPPLEMENTAL APPENDIX TO METZELER ET AL.: SPECTRUM AND PROGNOSTIC RELEVANCE OF DRIVER GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA SUPPLEMENTAL METHODS Treatment protocols In the AMLCG-1999 trial 1-3 (clinicaltrials.gov
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationNEW THERAPIES IN ACUTE MYELOID LEUKEMIA (AML) Maho Hibino, PharmD, BCOP Oncology Clinical Specialist Wake Forest Baptist Health August 3, 2018
NEW THERAPIES IN ACUTE MYELOID LEUKEMIA (AML) Maho Hibino, PharmD, BCOP Oncology Clinical Specialist Wake Forest Baptist Health August 3, 2018 OBJECTIVES Recognize new medications that received FDA approval
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationAML Handout August 3, 2018
NEW THERAPIES IN ACUTE MYELOID LEUKEMIA (AML) Maho Hibino, PharmD, BCOP Oncology Clinical Specialist Wake Forest Baptist Health August 3, OBJECTIVES Recognize new medications that received FDA approval
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationACUTE LEUKEMIA. Zwi N. Berneman University of Antwerp & Antwerp University Hospital. 16th Post-ASH Meeting Zaventem, 10 January 2014
ACUTE LEUKEMIA Zwi N. Berneman University of Antwerp & Antwerp University Hospital 16th Post-ASH Meeting Zaventem, 10 January 2014 ACUTE MYELOID LEUKEMIA HIGH-RISK AML Clinically and biologically distinct
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationFACULTY TRAINING TRANSCRIPT
FACULTY TRAINING TRANSCRIPT PROGRAM CURRICULUM REVIEWED BY: B. DOUGLAS SMITH, MD Professor of Oncology Johns Hopkins University, School of Medicine Baltimore, MD JONATHAN WEBSTER, MD Instructor of Oncology
More informationHighlights in acute leukemia
CONGRESS HIGHLIGHTS 28 Highlights in acute leukemia T. Feys, MSc, MBA SPECIAL EDITION There has been a long period of time without any new acute myeloid leukemia (AML) treatments. However, the tide has
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationDisclosures. Clinical Case Vignettes. Association of Northern California Oncologists (ANCO) Hematologic Malignancies Update. September 9, /12/17
Clinical Case Vignettes Association of Northern California Oncologists (ANCO) Hematologic Malignancies Update September 9, 2017 Brian Sworder MD, PhD, fellow (Stanford) bsworder@stanford.edu Disclosures
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationManagement of Myelodysplastic Syndromes
Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationJuan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1
Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1 Xin Hua Hospital, Shanghai, China 2 Oregon Health & Science University, Portland, OR, United States AML is a hematopoietic neoplasms characterized
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationLearning Objectives. Case A: Presentation. Case A Question Not included in Activity Survey. Acute Leukemia: Diagnosis and Prognosis
Learning Objectives Improve awareness of FDA-approved agents and/or therapies under development for the treatment of AML and ALL Incorporate FDA-approved agents and therapies under development into treatment
More informationPage: 1 of 12. Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Leukemia
Page: 1 of 12 Last Review Status/Date: September 2015 Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Description Treatment of acute myeloid leukemia (AML) is based upon risk stratification,
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationSupplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia
Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína
More informationAnthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia
Published Ahead of Print on June 27, 2014, as doi:10.3324/haematol.2014.109827. Copyright 2014 Ferrata Storti Foundation. Anthracycline dose intensification improves molecular response and outcome of patients
More informationASCO 2009 Leukemia MDS -Transplant
ASCO 2009 Leukemia MDS -Transplant Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Scottsdale, AZ, USA mesa.ruben@mayo.edu American Society of Hematology State-of-the-Art Symposium
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance
More informationGenetic Testing for FLT3 and NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia
Genetic Testing for FLT3 and NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia Policy Number: 2.04.124 Last Review: 09/2017 Origination: 9/2014 Next Review: 09/2018 Policy Blue
More informationHigh expression of HMGA2 independently predicts poor clinical outcomes in acute
SUPPLEMENTARY INFORMATION High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia Marquis M., et al. Page 1 of 39 TABLE OF CONTENTS METHODS... 4 Methods for cryopreservation
More informationNew and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)
Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber
More information